Inactivation of human norovirus surrogates by benzalkonium chloride, potassium peroxymonosulfate, tannic acid, and gallic acid.
Novel methods to effectively disinfect contact surfaces and prevent human norovirus transmission are essential. The effect of benzalkonium chloride (BAC), potassium peroxymonosulfate (KPMS), tannic acid (TA), and gallic acid (GA) on enteric virus surrogates, murine norovirus (MNV-1), feline calicivirus (FCV-F9), and bacteriophage MS2 was studied. Viruses at high (∼7 log₁₀ PFU/mL) or low (∼5 log₁₀ PFU/mL) titers were mixed with equal volumes of BAC (0.2, 0.5, and 1 mg/mL), KPMS (5, 10, and 20 mg/mL), TA (0.02 and 0.2 mg/mL), GA (0.2, 0.4, and 0.8 mg/mL), or water and incubated for 2 h at room temperature. Viral infectivity after triplicate treatments was evaluated using plaque assays in duplicate. Low titers of FCV-F9 and MNV-1 were completely reduced, while low-titer MS2 was reduced by 1.7-1.8 log₁₀ PFU/mL with BAC at all three concentrations. High-titer FCV-F9 was reduced by 2.87, 3.08, and 3.25 log₁₀ PFU/mL, and high-titer MNV-1 was reduced by 1.55, 2.32, and 2.75 log₁₀ PFU/mL with BAC at 0.1, 0.25, and 0.5 mg/mL, respectively. High-titer MS2 was reduced by ∼2 log₁₀ PFU/mL with BAC at all three concentrations. KPMS at all three concentrations reduced high and low titers of FCV-F9 and MS2 and low-titer MNV-1 to undetectable levels, while high-titer MNV-1 was reduced by 0.92 and 3.44 log₁₀ PFU/mL with KMPS at 2.5 and 5 mg/mL, respectively. TA at 0.2 mg/mL only reduced high-titer FCV-F9 by 0.98 log₁₀ PFU/mL and low-titer FCV-F9 by 1.95 log₁₀ PFU/mL. GA at 0.1, 0.2, and 0.4 mg/mL reduced low-titer FCV-F9 by 2.50, 2.36, and 0.86 log₁₀ PFU/mL, respectively with negligible effects against high-titer FCV-F9. BAC and KPMS show promise to be used as broad-spectrum contact surface disinfectants for prevention of noroviral surrogate contamination.
Department of Food Science and Technology, University of Tennessee-Knoxville, Knoxville, Tennessee 37996-4591, USA.
Xiaowei
X
Su
Doris H
DH
D'Souza
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology; D001435:Bacteriophages / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity; D001548:Benzalkonium Compounds / Q000494:pharmacology*; D017927:Calicivirus, Feline / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity; D002415:Cats; D002460:Cell Line; D004202:Disinfectants / Q000494:pharmacology*; D005517:Foodborne Diseases / Q000517:prevention & control; D005707:Gallic Acid / Q000494:pharmacology; D051379:Mice; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects; D029322:Norovirus / Q000187:drug effects* / Q000254:growth & development / Q000472:pathogenicity; D010545:Peroxides / Q000494:pharmacology*; D013634:Tannins / Q000494:pharmacology; D010948:Viral Plaque Assay
D000998:Antiviral Agents; D001548:Benzalkonium Compounds; D004202:Disinfectants; D010545:Peroxides; D013634:Tannins; C038288:peroxymonosulfate; D005707:Gallic Acid